Flowers Foods Sinks on Q2 Earnings
Flowers Foods, Inc. (NYSE: FLO) today reported financial results for the company's 12-week second quarter ended July 12, 2025.Net sales increased 1.5% to $1.243 billion as the Simple Mills acquisition benefit more than offset pricing/mix and volume declines.Net income decreased 12.8% to $58.4 million, representing 4.7% of sales, an 80-basis point decrease, primarily due to greater outside purchases, increased workforce-related costs, and higher interest expense. Adjusted net income decreased 16.0% to $63.4 million.Adjusted EBITDA decreased 4.0% to $137.7 million, representing 11.1% of net sales, a 60-basis point decrease.Diluted EPS decreased $0.04 to $0.28. Adjusted diluted EPS decreased $0.06 to $0.30.Simple Mills contributed $61.4 million in net sales, net loss of $2.1 million, $10.9 million to adjusted EBITDA, and ($0.01) diluted EPS.Said CEO Ryals McMullian, "Macroeconomic uncertainty and shifting consumer demand have continued to pressure the bread category, but our portfolio strategy has shown promise in offsetting those headwinds.” "We are proactively investing in innovation and M&A to transform our portfolio and align it with consumer demand for better-for-you and value-oriented products. These differentiated products enable us to target attractive opportunities in our existing categories, while expanding into adjacencies and new categories with exciting growth prospects.”FLO shares gave back 56 cents, or 3.4%, Friday to $16.02.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


